Loading...

Francis Yao, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, MSB
San Francisco CA 94117
Phone415-514-0332
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Donation After Circulatory Death Is Associated With Similar Posttransplant Survival in All but the Highest-Risk Hepatocellular Carcinoma Patients. Liver Transpl. 2020 Sep; 26(9):1100-1111. Silverstein J, Roll G, Dodge JL, Grab JD, Yao FY, Mehta N. PMID: 32531867.
      View in: PubMed   Mentions:    Fields:    
    2. Reply to HEP-20-0970. Hepatology. 2020 Jun 24. Mehta N, Yao FY. PMID: 32583439.
      View in: PubMed   Mentions:    Fields:    
    3. Bacchus Listed for a Liver Transplant: Comment. Anesthesiology. 2020 06; 132(6):1593. Kronish K, Freise CE, Yao FY. PMID: 32217868.
      View in: PubMed   Mentions:    Fields:    
    4. Liver Transplantation for Hepatocellular Carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference. Transplantation. 2020 Jun; 104(6):1136-1142. Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, Akamatsu N, Durand F, Ijzermans J, Polak W, Zheng S, Roberts JP, Sapisochin G, Hibi T, Kwan NM, Ghobrial M, Soin A. PMID: 32217938.
      View in: PubMed   Mentions:    Fields:    
    5. Unfair Advantages for Hepatocellular Carcinoma Patients Listed for Liver Transplant in Short-Wait Regions Following 2015 Hepatocellular Carcinoma Policy Change. Liver Transpl. 2020 May; 26(5):662-672. Brondfield MN, Dodge JL, Hirose R, Heimbach J, Yao FY, Mehta N. PMID: 31833634.
      View in: PubMed   Mentions:    Fields:    
    6. Hepatocellular carcinoma demonstrates heterogeneous growth patterns in a multi-center cohort of patients with cirrhosis. Hepatology. 2020 Feb 04. Rich NE, John BV, Parikh ND, Rowe I, Mehta N, Khatri G, Thomas SM, Anis M, Mendiratta-Lala M, Hernandez C, Odewole M, Sundaram LT, Konjeti VR, Shetty S, Shah T, Zhu H, Yopp AC, Hoshida Y, Yao FY, Marrero JA, Singal AG. PMID: 32017165.
      View in: PubMed   Mentions: 5     Fields:    
    7. Surveillance for HCC after Liver Transplantation: Increased monitoring may yield aggressive treatment options and improved postrecurrence survival. Transplantation. 2020 Jan 13. Lee DD, Sapisochin G, Mehta N, Gorgen A, Musto KR, Hajda H, Yao FY, Hodge DO, Carter RE, Harnois DM. PMID: 31972705.
      View in: PubMed   Mentions:    Fields:    
    8. Liver transplantation for hepatocellular carcinoma: Management after the transplant. Am J Transplant. 2020 02; 20(2):333-347. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, Pillai AA, Salgia R, Seetharam A, Sharma P, Sherman C, Tsoulfas G, Yao FY. PMID: 31710773.
      View in: PubMed   Mentions: 1     Fields:    
    9. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time. Hepatology. 2020 Mar; 71(3):943-954. Mehta N, Dodge JL, Grab JD, Yao FY. PMID: 31344273.
      View in: PubMed   Mentions: 3     Fields:    
    10. REPLY. Hepatology. 2019 10; 70(4):1491-1492. Mehta N, Dodge JL, Yao FY. PMID: 31095762.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Comparison of Liver Transplant Wait-List Outcomes Among Patients With Hepatocellular Carcinoma With Public vs Private Medical Insurance. JAMA Netw Open. 2019 08 02; 2(8):e1910326. Gutin L, Yao F, Dodge JL, Grab J, Mehta N. PMID: 31469395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Prospective Phase II trial of drug-eluting bead chemoembolization for liver transplant candidates with hepatocellular carcinoma and marginal hepatic reserve. J Hepatocell Carcinoma. 2019; 6:93-103. Fidelman N, Johanson C, Kohi MP, Kolli KP, Kohlbrenner RM, Lehrman ED, Taylor AG, Kelley RK, Yao FY, Roberts JP, Kerlan RK. PMID: 31355158.
      View in: PubMed   Mentions:
    13. Noninvasive estimation of pulmonary vascular resistance improves portopulmonary hypertension screening in liver transplant candidates. Clin Transplant. 2019 07; 33(7):e13585. DesJardin JT, Manicardi M, Svetlichnaya Y, Kolaitis NA, Papolos AI, Selby VN, Zier LS, Klein L, Aras MA, Yao FY, Roberts JP, De Marco T. PMID: 31074522.
      View in: PubMed   Mentions: 1     Fields:    
    14. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol. Hepatology. 2019 10; 70(4):1185-1196. Sinha J, Mehta N, Dodge JL, Poltavskiy E, Roberts J, Yao F. PMID: 30779440.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    15. Predictors of low risk for dropout from the liver transplant waiting list for hepatocellular carcinoma in long wait time regions: Implications for organ allocation. Am J Transplant. 2019 08; 19(8):2210-2218. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. PMID: 30861298.
      View in: PubMed   Mentions: 1     Fields:    
    16. What Are the Optimal Liver Transplantation Criteria for Hepatocellular Carcinoma? Clin Liver Dis (Hoboken). 2019 Jan; 13(1):20-25. Mehta N, Yao FY. PMID: 31168361.
      View in: PubMed   Mentions:
    17. Alpha-Fetoprotein Decrease from > 1,000 to < 500 ng/mL in Patients with Hepatocellular Carcinoma Leads to Improved Posttransplant Outcomes. Hepatology. 2019 03; 69(3):1193-1205. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 30548884.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    18. The mRECIST Classification Provides Insight into Tumor Biology for Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation. Liver Transpl. 2019 02; 25(2):228-241. Lee DD, Samoylova M, Mehta N, Musto KR, Roberts JP, Yao FY, Harnois DM. PMID: 30198150.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Distinguishing Tumor From Bland Portal Vein Thrombus in Liver Transplant Candidates With Hepatocellular Carcinoma: the A-VENA Criteria. Liver Transpl. 2019 02; 25(2):207-216. Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. PMID: 30246323.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    20. Screening for Hepatocellular Carcinoma to Improve Cancer-Related Mortality: Looking Behind When We Should Be Looking Ahead. Gastroenterology. 2019 03; 156(4):1215-1217. Mehta N, Monto A, Yao FY. PMID: 30543796.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    21. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation. HPB (Oxford). 2019 06; 21(6):731-738. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, Yao FY, Muiesan P, Mazzaferro V, Sapisochin G. PMID: 30391218.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Increasing Liver Transplantation Wait-List Dropout for Hepatocellular Carcinoma With Widening Geographical Disparities: Implications for Organ Allocation. Liver Transpl. 2018 10; 24(10):1346-1356. Mehta N, Dodge JL, Hirose R, Roberts JP, Yao FY. PMID: 30067889.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. Predictors of Ultrasound Failure to Detect Hepatocellular Carcinoma. Liver Transpl. 2018 09; 24(9):1171-1177. Samoylova ML, Mehta N, Roberts JP, Yao FY. PMID: 29781162.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018 08; 68(2):449-461. Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. PMID: 29476694.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    25. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma. Transplantation. 2018 05; 102(5):816-822. Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. PMID: 29505494.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    26. History of Marijuana Use Does Not Affect Outcomes on the Liver Transplant Waitlist. Transplantation. 2018 05; 102(5):794-802. Kotwani P, Saxena V, Dodge JL, Roberts J, Yao F, Hameed B. PMID: 29319619.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Living donor liver transplantation for hepatocellular carcinoma: To expand (beyond Milan) or downstage (to Milan)? Liver Transpl. 2018 03; 24(3):327-329. Mehta N, Yao FY. PMID: 29351366.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database. Am J Transplant. 2018 05; 18(5):1206-1213. Mehta N, Dodge JL, Roberts JP, Yao FY. PMID: 29068145.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Con: Treating hepatitis C virus With direct-acting antivirals: Fear not the perceived threat of hepatocellular carcinoma. Liver Transpl. 2017 12; 23(12):1596-1600. Mehta N, Yao FY. PMID: 29024442.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    30. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study. Clin Gastroenterol Hepatol. 2018 06; 16(6):955-964. Mehta N, Guy J, Frenette CT, Dodge JL, Osorio RW, Minteer WB, Roberts JP, Yao FY. PMID: 29175528.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    31. Misdiagnosis of hepatocellular carcinoma in patients receiving no local-regional therapy prior to liver transplant: An analysis of the Organ Procurement and Transplantation Network explant pathology form. Clin Transplant. 2017 Nov; 31(11). Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 28881064.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    32. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot". Transplantation. 2017 09; 101(9):2071-2078. Mehta N, Heimbach J, Lee D, Dodge JL, Harnois D, Burns J, Sanchez W, Roberts JP, Yao FY. PMID: 28353492.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    33. Liver transplantation recipients with nonalcoholic steatohepatitis have lower risk hepatocellular carcinoma. Liver Transpl. 2017 08; 23(8):1015-1022. Lewin SM, Mehta N, Kelley RK, Roberts JP, Yao FY, Brandman D. PMID: 28340509.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    34. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant. JAMA Oncol. 2017 Apr 01; 3(4):493-500. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, Lee D, Burns JM, Sanchez W, Greig PD, Grant DR, Roberts JP, Yao FY. PMID: 27838698.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    35. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology. 2016 12; 151(6):1062-1065. Mehta N, Yao FY. PMID: 27983951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Reply. Liver Transpl. 2016 08; 22(8):1164-5. Mehta N, Yao FY. PMID: 27097078.
      View in: PubMed   Mentions:    Fields:    
    37.  Increased hepatocellular carcinoma recurrence in women compared to men with high alpha fetoprotein at liver transplant. Ann Hepatol. 2016 Jul-Aug; 15(4):545-9. Sarkar M, Dodge JL, Roberts JP, Terrault N, Yao F, Mehta N. PMID: 27236153.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    38. Lack of benefits of mammalian target of rapamycin inhibitor in patients transplanted for hepatocellular carcinoma: Is this the end of the story? Liver Transpl. 2016 05; 22(5):582-4. Mehta N, Roberts JP, Yao FY. PMID: 26951991.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    39. Hepatocellular cancer as indication for liver transplantation: pushing beyond Milan. Curr Opin Organ Transplant. 2016 Apr; 21(2):91-8. Mehta N, Yao FY. PMID: 26807513.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    40. Nucleos(t)ide analogs reduce the risk of hepatitis B-associated hepatocellular carcinoma: A can't miss proposition? Hepatology. 2016 May; 63(5):1415-7. Mehta N, Yao FY. PMID: 26679367.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl. 2016 Feb; 22(2):178-87. Mehta N, Sarkar M, Dodge JL, Fidelman N, Roberts JP, Yao FY. PMID: 26479422.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    42. Minimal Transplant Survival Benefit for Hepatocellular Carcinoma: Is it Real or an Overestimation of Waitlist Life Expectancy? Gastroenterology. 2016 Feb; 150(2):533-4. Mehta N, Heimbach J, Hirose R, Roberts JP, Yao FY. PMID: 26718172.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Hepatology. 2016 Mar; 63(3):1014-25. Yao FY, Fidelman N. PMID: 26560491.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Liver transplantation for hepatocellular carcinoma: analysis of factors predicting outcome in 1074 patients in OPTN Region 5. Clin Transplant. 2015 Jun; 29(6):506-12. Macdonald B, Sewell JL, Harper AM, Roberts JP, Yao FY. PMID: 25777321.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Implications of discordant findings between hepatic angiography and cross-sectional imaging in transplant candidates with hepatocellular carcinoma. Liver Transpl. 2015 Apr; 21(4):454-67. Young K, Fidelman N, Yao FY, Hills NK, Kohi MP, Kolli KP, Taylor AG, Kerlan RK. PMID: 25678220.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls. BMC Cancer. 2015 Mar 31; 15:206. Kelley RK, Magbanua MJ, Butler TM, Collisson EA, Hwang J, Sidiropoulos N, Evason K, McWhirter RM, Hameed B, Wayne EM, Yao FY, Venook AP, Park JW. PMID: 25884197.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    47. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015 Jun; 61(6):1968-77. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, Hirose R, Fidelman N, Kerlan RK, Roberts JP. PMID: 25689978.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    48. Potential role of the donor in hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015 Feb; 21(2):187-94. Vagefi PA, Dodge JL, Yao FY, Roberts JP. PMID: 25371243.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    49. Evaluating the validity of model for end-stage liver disease exception points for hepatocellular carcinoma patients with multiple nodules <2 cm. Clin Transplant. 2015 Jan; 29(1):52-9. Samoylova ML, Dodge JL, Mehta N, Yao FY, Roberts JP. PMID: 25366656.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    50. Response to letter to the editors. Liver Transpl. 2014 Oct; 20(10):1285. Yao FY, Hameed B, Mehta N, Roberts JP. PMID: 25155484.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    51. Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization. Liver Transpl. 2014 Oct; 20(10):1221-8. Goel A, Mehta N, Guy J, Fidelman N, Yao F, Roberts J, Terrault N. PMID: 25045002.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. Transplantation. 2014 Sep 15; 98(5):557-62. Sharpton SR, Feng S, Hameed B, Yao F, Lai JC. PMID: 24717221.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    53. Restricting liver transplant recipients to younger donors does not increase the wait-list time or the dropout rate: the hepatitis C experience. Liver Transpl. 2014 Oct; 20(10):1202-10. Flemming JA, Vagefi PA, Freise CE, Yao FY, Terrault NA. PMID: 24961679.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014 Aug; 20(8):945-51. Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. PMID: 24797281.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    55. Time to transplantation as a predictor of hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2014 Aug; 20(8):937-44. Samoylova ML, Dodge JL, Yao FY, Roberts JP. PMID: 24797145.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    56. Outcomes after liver transplantation for patients with hepatocellular carcinoma and a low risk of dropout from the transplant waiting list. Liver Transpl. 2014 May; 20(5):627-8. Mehta N, Dodge JL, Roberts JP, Hirose R, Yao FY. PMID: 24493311.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Conundrum of treatment for early-stage hepatocellular carcinoma: radiofrequency ablation instead of liver transplantation as the first-line treatment? Liver Transpl. 2014 Mar; 20(3):257-60. Yao FY. PMID: 24493329.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    58. Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl. 2013 Dec; 19(12):1343-53. Mehta N, Dodge JL, Goel A, Roberts JP, Hirose R, Yao FY. PMID: 24285611.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    59. Validating posttransplant hepatocellular carcinoma recurrence data in the United Network for Organ Sharing database. Liver Transpl. 2013 Dec; 19(12):1318-23. Samoylova ML, Dodge JL, Vittinghoff E, Yao FY, Roberts JP. PMID: 24039140.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    60. Moving past "One size (and number) fits all" in the selection of candidates with hepatocellular carcinoma for liver transplantation. Liver Transpl. 2013 Oct; 19(10):1055-8. Mehta N, Yao FY. PMID: 23959652.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    61. Reply: To PMID 23333661. Clin Gastroenterol Hepatol. 2013 Dec; 11(12):1674. Yao F, Mehta N. PMID: 24035772.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    62. Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013 May; 11(5):572-8. Mehta N, Fidelman N, Sarkar M, Yao FY. PMID: 23333661.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction. Liver Transpl. 2013 Feb; 19(2):164-73. Garwood ER, Fidelman N, Hoch SE, Kerlan RK, Yao FY. PMID: 23008091.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    64. Risk factors for liver transplant waitlist dropout in patients with hepatocellular carcinoma. Clin Transplant. 2012 Jul-Aug; 26(4):E359-64. Park SJ, Freise CE, Hirose R, Kerlan RK, Yao FY, Roberts JP, Vagefi PA. PMID: 22693962.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    65. Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation. Liver Transpl. 2012 Jun; 18(6):727-36. Kwan SW, Fidelman N, Ma E, Kerlan RK, Yao FY. PMID: 22344899.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    66. Multidisciplinary management of hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2012 Apr; 10(4):354-62. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. PMID: 22083023.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    67. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl. 2011 Oct; 17 Suppl 2:S109-16. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. PMID: 21584927.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    68. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transpl. 2011 Aug; 17(8):934-42. Sapisochin G, Fidelman N, Roberts JP, Yao FY. PMID: 21438129.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    69. Do preoperative inflammatory markers impact on outcome after liver transplantation for hepatocellular carcinoma? Ann Surg. 2011 Aug; 254(2):383; author reply 383-4. Sapisochin G, Yao FY, Roberts JP. PMID: 21694577.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    70. Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2011 Mar-Apr; 25(2):283-91. Ladabaum U, Cheng SL, Yao FY, Roberts JP. PMID: 20156221.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Hepatocellular carcinoma: Ablate and wait versus rapid transplantation. Liver Transpl. 2010 Aug; 16(8):925-9. Roberts JP, Venook A, Kerlan R, Yao F. PMID: 20658555.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    72. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology. 2008 Sep; 48(3):819-27. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, Peters M, Terrault N, Freise CE, Ascher NL, Roberts JP. PMID: 18688876.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    73. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant. 2008 Oct; 8(10):1982-9. Yao FY. PMID: 18727702.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    74. Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation. Curr Opin Organ Transplant. 2008 Jun; 13(3):234-40. Hanje AJ, Yao FY. PMID: 18685309.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    75. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008 Apr; 15(4):1001-7. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, Bhoori S, Lee SG. PMID: 18236119.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    76. Liver transplantation at UCSF--a 20-year experience. Clin Transpl. 2008; 119-25. Hirose R, Yao F, Stock P, Roberts J, Ascher N. PMID: 19708450.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant. 2007 Nov; 7(11):2587-96. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. PMID: 17868066.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    78. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Hepatol Res. 2007 Sep; 37 Suppl 2:S267-74. Yao FY. PMID: 17877493.
      View in: PubMed   Mentions:
    79. Liver transplantation for hepatocellular carcinoma: the hepatitis C quandary. Liver Transpl. 2007 Jun; 13(6):783-5. Yao FY. PMID: 17538996.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    80. Short waitlist time does not adversely impact outcome following liver transplantation for hepatocellular carcinoma. Am J Transplant. 2007 Jun; 7(6):1594-600. Chao SD, Roberts JP, Farr M, Yao FY. PMID: 17430396.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    81. Should surveillance for hepatocellular carcinoma be increased in patients with cirrhosis and small liver nodules? Nat Clin Pract Gastroenterol Hepatol. 2006 Oct; 3(10):544-5. Yao FY. PMID: 17008923.
      View in: PubMed   Mentions: 3     Fields:    
    82. De novo malignancies following liver transplantation: a case-control study with long-term follow-up. Clin Transplant. 2006 Sep-Oct; 20(5):617-23. Yao FY, Gautam M, Palese C, Rebres R, Terrault N, Roberts JP, Peters MG. PMID: 16968488.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    83. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation--yes. Semin Liver Dis. 2006 Aug; 26(3):239-47. Yao FY. PMID: 16850373.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    84. Selection criteria for liver transplantation in patients with hepatocellular carcinoma: beyond tumor size and number? Liver Transpl. 2006 Aug; 12(8):1189-91. Yao FY. PMID: 16868948.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005 Dec; 11(12):1505-14. Yao FY, Hirose R, LaBerge JM, Davern TJ, Bass NM, Kerlan RK, Merriman R, Feng S, Freise CE, Ascher NL, Roberts JP. PMID: 16315294.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    86. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant. 2005 Aug; 19(4):501-6. Cruz E, Ascher NL, Roberts JP, Bass NM, Yao FY. PMID: 16008595.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    87. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005 Apr; 5(4 Pt 1):795-804. Yao FY, Kinkhabwala M, LaBerge JM, Bass NM, Brown R, Kerlan R, Venook A, Ascher NL, Emond JC, Roberts JP. PMID: 15760404.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    88. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol. 2005 Jan; 3(1):75-84. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. PMID: 15645408.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    89. Applying expanded criteria to liver transplantation for hepatocellular carcinoma: too much too soon, or is now the time? Liver Transpl. 2004 Jul; 10(7):919-21. Yao FY, Roberts JP. PMID: 15237378.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    90. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy. Liver Transpl. 2004 May; 10(5):621-30. Yao FY, Bass NM, Ascher NL, Roberts JP. PMID: 15108253.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    91. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology. 2004 Jan; 39(1):230-8. Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. PMID: 14752842.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    92. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant. 2003 Nov; 3(11):1413-7. Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. PMID: 14525603.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    93. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl. 2003 Jul; 9(7):684-92. Yao FY, Bass NM, Nikolai B, Merriman R, Davern TJ, Kerlan R, Ascher NL, Roberts JP. PMID: 12827553.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    94. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J Clin Gastroenterol. 2003 May-Jun; 36(5):440-2. Yao FY. PMID: 12702990.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    95. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002 Oct; 8(10):873-83. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, Ascher NL, Roberts JP. PMID: 12360427.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    96. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002 Sep; 8(9):765-74. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. PMID: 12200775.
      View in: PubMed   Mentions: 90     Fields:    Translation:Humans
    97. Hepatitis C and hepatocellular carcinoma. Curr Treat Options Oncol. 2001 Dec; 2(6):473-83. Yao F, Terrault N. PMID: 12057093.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    98. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology. 2001 Aug; 34(2):411-6. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. PMID: 11481627.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    99. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001 Jun; 33(6):1394-403. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, Ascher NL, Roberts JP. PMID: 11391528.
      View in: PubMed   Mentions: 414     Fields:    Translation:Humans
    100. The role of the interventional radiologist. Transjugular procedures. Gastrointest Endosc Clin N Am. 2001 Jan; 11(1):131-61. Bass NM, Yao FY. PMID: 11175979.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    101. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol. 2000 Aug; 33(2):301-7. Yao FY, Bass NM. PMID: 10952248.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    102. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg. 1999 Nov; 5(6):491-6. Yao FY, Osorio RW, Roberts JP, Poordad FF, Briceno MN, Garcia-Kennedy R, Gish RR. PMID: 10545536.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    103. Treatment of chronic hepatitis B: new antiviral therapies. Curr Gastroenterol Rep. 1999 Feb-Mar; 1(1):20-6. Yao F, Gish RG. PMID: 10980922.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Francis's Networks
    Concepts (213)
    Derived automatically from this person's publications.
    _
    Co-Authors (48)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _